Literature DB >> 21339733

TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression.

M Seux1, S Peuget, M P Montero, C Siret, V Rigot, P Clerc, V Gigoux, E Pellegrino, L Pouyet, P N'Guessan, S Garcia, M Dufresne, J L Iovanna, A Carrier, F André, N J Dusetti.   

Abstract

Tumor protein 53 induced nuclear protein 1 (TP53INP1) is a p53 target gene that induces cell growth arrest and apoptosis by modulating p53 transcriptional activity. TP53INP1 interacts physically with p53 and is a major player in the p53-driven oxidative stress response. Previously, we demonstrated that TP53INP1 is downregulated in an early stage of pancreatic cancerogenesis and when restored is able to suppress pancreatic tumor development. TP53INP1 downregulation in pancreas is associated with an oncogenic microRNA miR-155. In the present work, we studied the effects of TP53INP1 on cell migration. We found that TP53INP1 inactivation correlates with increased cell migration both in vivo and in vitro. The impact of TP53INP1 expression on cell migration was studied in different cellular contexts: mouse embryonic fibroblast and different pancreatic cancer cell lines. Its expression decreases cell migration by the transcriptional downregulation of secreted protein acidic and rich in cysteine (SPARC). SPARC is a matrix cellular protein, which governs diverse cellular functions and has a pivotal role in regulating cell-matrix interactions, cellular proliferation and migration. SPARC was also showed to be upregulated in normal pancreas and in pancreatic intraepithelial neoplasia lesions in a pancreatic adenocarcinoma mouse model only in the TP53INP1-deficient animals. This novel TP53INP1 activity on the regulation of SPARC expression could explain in part its tumor suppressor function in pancreatic adenocarcinoma by modulating cellular spreading during the metastatic process.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21339733     DOI: 10.1038/onc.2011.25

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

Review 1.  Human correlates of provocative questions in pancreatic pathology.

Authors:  Oliver G McDonald; Anirban Maitra; Ralph H Hruban
Journal:  Adv Anat Pathol       Date:  2012-11       Impact factor: 3.875

2.  Development of an ELISA detecting Tumor Protein 53-Induced Nuclear Protein 1 in serum of prostate cancer patients.

Authors:  Houda Saadi; Marion Seillier; Maria José Sandi; Sylvain Peuget; Christine Kellenberger; Gwenaëlle Gravis; Nelson J Dusetti; Juan L Iovanna; Palma Rocchi; Mohamed Amri; Alice Carrier
Journal:  Results Immunol       Date:  2013-05-28

3.  Linking Alzheimer's disease and type 2 diabetes: Novel shared susceptibility genes detected by cFDR approach.

Authors:  Xia-Fang Wang; Xu Lin; Ding-You Li; Rou Zhou; Jonathan Greenbaum; Yuan-Cheng Chen; Chun-Ping Zeng; Lin-Ping Peng; Ke-Hao Wu; Zeng-Xin Ao; Jun-Min Lu; Yan-Fang Guo; Jie Shen; Hong-Wen Deng
Journal:  J Neurol Sci       Date:  2017-08-01       Impact factor: 3.181

Review 4.  Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.

Authors:  Thomas S Frank; Xiaotian Sun; Yuqing Zhang; Jingxuan Yang; William E Fisher; Marie-Claude Gingras; Min Li
Journal:  Cancer Lett       Date:  2015-04-15       Impact factor: 8.679

Review 5.  Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer.

Authors:  Siuwah Tang; Jillian Bonaroti; Sebnem Unlu; Xiaoyan Liang; Daolin Tang; Herbert J Zeh; Michael T Lotze
Journal:  Pancreas       Date:  2013-07       Impact factor: 3.327

Review 6.  Personalising pancreas cancer treatment: When tissue is the issue.

Authors:  Katrin M Sjoquist; Venessa T Chin; Lorraine A Chantrill; Chelsie O'Connor; Chris Hemmings; David K Chang; Angela Chou; Marina Pajic; Amber L Johns; Adnan M Nagrial; Andrew V Biankin; Desmond Yip
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

7.  A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.

Authors:  Lindsay B Alcaraz; Aude Mallavialle; Timothée David; Danielle Derocq; Frédéric Delolme; Cindy Dieryckx; Caroline Mollevi; Florence Boissière-Michot; Joëlle Simony-Lafontaine; Stanislas Du Manoir; Pitter F Huesgen; Christopher M Overall; Sophie Tartare-Deckert; William Jacot; Thierry Chardès; Séverine Guiu; Pascal Roger; Thomas Reinheckel; Catherine Moali; Emmanuelle Liaudet-Coopman
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

Review 8.  Looking to the future: biomarkers in the management of pancreatic adenocarcinoma.

Authors:  Jennifer L Spratlin; Karen E Mulder
Journal:  Int J Mol Sci       Date:  2011-09-14       Impact factor: 5.923

9.  MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo.

Authors:  Feizhou Jiang; Te Liu; Yinyan He; Qin Yan; Xiaoyue Chen; Hui Wang; Xiaoping Wan
Journal:  BMC Cancer       Date:  2011-10-05       Impact factor: 4.430

10.  Tumor Protein 53-Induced Nuclear Protein 1 Enhances p53 Function and Represses Tumorigenesis.

Authors:  Jeyran Shahbazi; Richard Lock; Tao Liu
Journal:  Front Genet       Date:  2013-05-13       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.